GlassScriptPhysician profile
Robert B Kennedy
NPI 1780744870
$1,924.83
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $891 · 2021: $326 · 2022: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $571.22 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $456.84 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.44 | 2019-2022 | |
| Abbvie INC. | $134.74 | 2019-2022 | |
| Lilly USA, LLC | $117.91 | 2020-2022 | |
| Glaxosmithkline, LLC. | $98.46 | 2020-2022 | |
| Pfizer INC. | $69.70 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.55 | 2019-2020 | |
| Amarin Pharma, INC. | $58.89 | 2019 | |
| Eisai INC. | $57.04 | 2020-2021 | |
| Amgen INC. | $38.48 | 2020-2021 | |
| Gilead Sciences, INC. | $32.69 | 2020 | |
| Allergan, INC. | $25.73 | 2020 | |
| Novartis Pharmaceuticals Corporation | $22.41 | 2019 | |
| Boston Scientific Corporation | $19.36 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.